Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Preclinical Emavusertib + BTKi Synergy AACR-NCI-EORTC Poster 2023

Monday, October 16, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Curis Inc. presented a poster on the preclinical synergy of Emavusertib and BTK inhibitors at the AACR-NCI-EORTC conference. The research highlights potential advancements in treatment strategies for various lymphomas. The poster emphasizes the role of Emavusertib in combination therapies, although specific results or outcomes were not detailed in the article.
Price reaction · baseline $103.124 (2023-10-16T13:34:00.000Z) · hit during market hours · 2 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-2.8%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What was presented at the AACR-NCI-EORTC conference?

Curis presented a poster on the preclinical synergy of Emavusertib and BTK inhibitors.

What is Emavusertib used for?

Emavusertib is being investigated for its potential in combination therapies for lymphomas.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis Emavusertib BTK inhibitors AACR-NCI-EORTC lymphoma
Last updated: Oct 16, 2023

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →